These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26187127)

  • 1. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
    Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
    Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
    Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
    Shafi AA; Cox MB; Weigel NL
    Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.
    O'Neill D; Jones D; Wade M; Grey J; Nakjang S; Guo W; Cork D; Davies BR; Wedge SR; Robson CN; Gaughan L
    Oncotarget; 2015 Sep; 6(28):26029-40. PubMed ID: 26267320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
    Lallous N; Volik SV; Awrey S; Leblanc E; Tse R; Murillo J; Singh K; Azad AA; Wyatt AW; LeBihan S; Chi KN; Gleave ME; Rennie PS; Collins CC; Cherkasov A
    Genome Biol; 2016 Jan; 17():10. PubMed ID: 26813233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
    Qiao Y; Feng FY; Wang Y; Cao X; Han S; Wilder-Romans K; Navone NM; Logothetis C; Taichman RS; Keller ET; Palapattu GS; Alva AS; Smith DC; Tomlins SA; Chinnaiyan AM; Morgan TM
    Neoplasia; 2016 Jan; 18(1):1-9. PubMed ID: 26806347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Yi Q; Han X; Yu HG; Chen HY; Qiu D; Su J; Lin R; Batist G; Wu JH
    Oncogene; 2024 May; 43(20):1522-1533. PubMed ID: 38532114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
    Ferraldeschi R; Welti J; Powers MV; Yuan W; Smyth T; Seed G; Riisnaes R; Hedayat S; Wang H; Crespo M; Nava Rodrigues D; Figueiredo I; Miranda S; Carreira S; Lyons JF; Sharp S; Plymate SR; Attard G; Wallis N; Workman P; de Bono JS
    Cancer Res; 2016 May; 76(9):2731-42. PubMed ID: 27197266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
    Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
    Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.
    Xu P; Yang JC; Ning S; Chen B; Nip C; Wei Q; Liu L; Johnson OT; Gao AC; Gestwicki JE; Evans CP; Liu C
    Pharmacol Res; 2023 Mar; 189():106692. PubMed ID: 36773708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
    Pollock JA; Wardell SE; Parent AA; Stagg DB; Ellison SJ; Alley HM; Chao CA; Lawrence SA; Stice JP; Spasojevic I; Baker JG; Kim SH; McDonnell DP; Katzenellenbogen JA; Norris JD
    Nat Chem Biol; 2016 Oct; 12(10):795-801. PubMed ID: 27501397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
    Zhou L; Zhang C; Yang X; Liu L; Hu J; Hou Y; Tao H; Sugimura H; Chen Z; Wang L; Chen K
    Clin Transl Med; 2021 Jun; 11(6):e449. PubMed ID: 34185414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Efficacy of Gnetin C as Dual-Targeted Therapy for Castrate-Resistant Prostate Cancer.
    Campanelli G; Deabel RA; Puaar A; Devarakonda LS; Parupathi P; Zhang J; Waxner N; Yang C; Kumar A; Levenson AS
    Mol Nutr Food Res; 2023 Dec; 67(24):e2300479. PubMed ID: 37863824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor.
    Dagar M; Singh JP; Dagar G; Tyagi RK; Bagchi G
    J Biol Chem; 2019 May; 294(22):8699-8710. PubMed ID: 30992362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.
    Chakraborty PK; Mustafi SB; Ganguly S; Chatterjee M; Raha S
    Cancer Sci; 2008 Jun; 99(6):1109-16. PubMed ID: 18429957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells.
    Qin Z; Ou S; Xu L; Sorensen K; Zhang Y; Hu DP; Yang Z; Hu WY; Chen F; Prins GS
    Chem Biol Drug Des; 2021 May; 97(5):1059-1078. PubMed ID: 33470049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
    Hinneh JA; Gillis JL; Mah CY; Irani S; Shrestha RK; Ryan NK; Atsushi E; Nassar ZD; Lynn DJ; Selth LA; Kato M; Centenera MM; Butler LM
    Br J Cancer; 2023 Oct; 129(8):1350-1361. PubMed ID: 37673961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent anti-proliferative, pro-apoptotic activity of the Maytenus royleanus extract against prostate cancer cells: evidence in in-vitro and in-vivo models.
    Shabbir M; Syed DN; Lall RK; Khan MR; Mukhtar H
    PLoS One; 2015; 10(3):e0119859. PubMed ID: 25798940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the androgen receptor pathway in prostate cancer.
    Chen Y; Sawyers CL; Scher HI
    Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.